IMPACT OF BODY COMPOSITION ON PHARMACOKINETICS OF DOXORUBICIN

身体成分对阿霉素药代动力学的影响

• 批准号: 7374951
• 负责人: STACEY L BERG
• 金额: $ 0.25万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374951
• 关键词: IMPACT; BODY; COMPOSITION; PHARMACOKINETICS; DOXORUBICIN

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Glaser Pediatric Research Network, an innovative and collaborative partnership, linking scientific centers to accelerate progress on serious and life-threatening pediatric illnesses. A primary objective of the Glaser Pediatric Research Network is to ensure that, as new therapies are developed, physicians learn more quickly about their pediatric applications. The participating centers are BCM, Harvard, Stanford, UCLA, UCSF.The pharmacokinetic behavior of doxorubicin as it relates to body mass index and body composition has not been well characterized. This protocol, being performed within the Glaser Pediatric Research Network, is designed to obtain detailed information on the impact of body composition on the pharmacokinetic behavior of doxorubicin after a single intravenous dose in children 21 years of age or younger. There is no efficacy component. Approximately 45 children will be enrolled. The information gained from this study could be very important in developing dosing strategies for doxorubicin in the obese patient population. HYPOTHESIS Body composition may affect the pharmacokinetic parameters of doxorubicin. In particular, patients who are obese by body mass index criteria or who have a high percentage of body fat as measured by DEXA scanning may have decreased doxorubicin clearance. SPECIFIC AIMSPrimary: To evaluate the relationship between obesity and doxorubicin pharmacokinetics in children.Secondary: To determine body composition in children who are categorized as obese/non-obese based on body mass index (BMI).

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。 Glaser儿科研究网络是一种创新且合作的伙伴关系，将科学中心联系起来，以加速严重和威胁生命的儿科疾病的进展。 Glaser小儿研究网络的主要目的是确保随着新疗法的发展，医生对其小儿应用的了解更快。参与中心是BCM，哈佛，斯坦福大学，加州大学洛杉矶分校，UCSF。阿霉素的药代动力学行为与体重指数和身体成分有关，尚未得到很好的特征。该方案是在Glaser小儿研究网络中执行的，旨在获取有关人体成分对21岁或以下的儿童单次静脉注射剂量后对身体组成对药代动力学行为的影响的详细信息。没有疗效组件。大约有45名儿童将入学。从这项研究中获得的信息对于制定肥胖患者人群中阿霉素的剂量策略可能非常重要。假设体的组成可能会影响阿霉素的药代动力学参数。特别是，按体重指数标准肥胖的患者或通过DEXA扫描测量的体内脂肪比例高的患者可能会降低阿霉素清除率。具体目的：评估儿童肥胖与阿霉素药代动力学之间的关系。辅助：确定基于体重指数（BMI）被归类为肥胖/非肥胖的儿童的身体成分。